Vernalis plc (VER) Price Target Increased to GBX 88 by Analysts at Canaccord Genuity
Vernalis plc (LON:VER) had its price objective raised by Canaccord Genuity from GBX 84 ($1.10) to GBX 88 ($1.15) in a report issued on Thursday morning. The firm currently has a buy rating on the stock.
A number of other equities research analysts also recently commented on VER. Stifel Nicolaus reiterated a buy rating on shares of Vernalis plc in a report on Friday, June 24th. Panmure Gordon reiterated a buy rating and set a GBX 76 ($0.99) price target on shares of Vernalis plc in a report on Friday, July 8th. Shore Capital reiterated a house stock rating on shares of Vernalis plc in a report on Friday, July 8th. Finally, N+1 Singer reiterated a hold rating and set a GBX 46 ($0.60) price target on shares of Vernalis plc in a report on Thursday. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Vernalis plc presently has a consensus rating of Buy and a consensus price target of GBX 73 ($0.95).
Vernalis plc (LON:VER) opened at 41.489 on Thursday. Vernalis plc has a one year low of GBX 31.00 and a one year high of GBX 79.00. The firm has a 50-day moving average price of GBX 43.70 and a 200 day moving average price of GBX 45.74. The company’s market cap is GBX 184.68 million.
Vernalis plc Company Profile
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Stock Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related stocks with our FREE daily email newsletter.